Levetiracetam Solution
Product Images NDC 65862-250

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 65862-250). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
A vertical bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1' comparing placebo with two doses of Levetiracetam oral solution (1000 mg/day and 3000 mg/day). The chart shows percent of patients who responded, with placebo at 7.4%, Levetiracetam 1000 mg/day at 37.1%, and Levetiracetam 3000 mg/day at 39.6%. Statistically significant differences versus placebo are indicated.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
A bar graph titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A,' displaying the percentage of patients responding to treatment. Three bars represent placebo and two dosages of Levetiracetam (1000 mg/day and 2000 mg/day), showing increasing response rates of 6.3%, 20.8%, and 35.2%, respectively, with a note indicating statistical significance versus placebo.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' comparing placebo and Levetiracetam 3000 mg/day. The vertical axis shows percentage of patients, with placebo at 14.4% and Levetiracetam at 39.4%, indicating a statistically significant difference.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
A bar chart titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' comparing the percentage of patients responding to placebo (19.6%) versus Levetiracetam (44.6%). The chart shows response rates on the vertical axis as percentages, with a note indicating statistical significance between Levetiracetam and placebo groups.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
Bar chart titled 'Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5,' comparing placebo and Levetiracetam groups. The chart shows percent of patients responding, with placebo at 19.6% and Levetiracetam at 43.1%, with a note indicating statistical significance for Levetiracetam versus placebo.*
FDA Label Image

Table 15: Median Percent Reduction From Baseline In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Table 15: Median Percent Reduction From Baseline In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
Bar chart showing responder rates with at least 50% reduction in PGTC seizure frequency per week in Study 7. The chart compares placebo (45.2% responders, N=84) to Levetiracetam (72.2% responders, N=79), indicating a statistically significant higher responder rate for Levetiracetam versus placebo.*
FDA Label Image

Package Label-principal Display Panel (100 mg/mL (473 mL Bottle))

Package Label-principal Display Panel (100 mg/mL (473 mL Bottle))
Levetiracetam Oral Solution USP 100 mg/mL label from Aurobindo Pharma Limited. The label includes NDC 65862-250-47, volume 473 mL, and storage instructions. Distributed by Aurobindo Pharma USA, Inc., East Windsor, NJ. The label highlights pharmacist dispensing instructions and a warning to keep out of reach of children.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)
Chemical structure of Levetiracetam, showing its molecular arrangement with the pyrrolidone ring and associated side groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.